SecBot SecBot
Biotech Drug Report Generated Oct 28, 2026

PONVORY

VNDA·Vanda Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially marketed (FDA approval March 2021).
Why 4/10
PONVORY is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard, dated catalyst for Vanda is the imsidolimab PDUFA on December 12, 2026, which is a different drug. PONVORY contributes roughly 13% of Vanda's revenue, so its commercial trajectory is not a binary event. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5.
Actionable Insight NEUTRAL

PONVORY itself has no upcoming binary catalyst; the next major Vanda event is the imsidolimab (Quimilza) PDUFA on December 12, 2026 for generalized pustular psoriasis, a separate drug. Watch Q3 2026 earnings (released today, Oct 28) for PONVORY's sales trajectory and any commentary on formulary access or market share trends in the competitive S1P modulator class.

Price Chart

Loading chart...

Executive Summary

PONVORY (ponesimod) is an FDA-approved once-daily oral S1P1 receptor modulator for relapsing forms of multiple sclerosis in adults, originally developed by Actelion/Janssen (Johnson & Johnson) and approved in March 2021. Vanda Pharmaceuticals (VNDA) acquired U.S. and Canadian rights in December 2023 for $100M upfront and completed the FDA marketing authorization transfer in 2025. PONVORY generated $27.4M in net product sales for Vanda in FY2025 (roughly 13% of total company revenue), with Q3 2026 sales of $7.7M (up 10% YoY). The drug faces stiff competition from other S1P modulators including generic fingolimod (Gilenya), Mayzent, and Zeposia. With no pending regulatory catalyst for PONVORY itself, Vanda's next major binary event is the imsidolimab PDUFA on December 12, 2026, a separate drug for generalized pustular psoriasis.

How It Works

PONVORY is a once-daily oral pill that works as a selective S1P1 receptor modulator. It traps certain white blood cells (lymphocytes) in lymph nodes, preventing them from entering the bloodstream and reaching the brain and spinal cord, where they would otherwise cause the inflammatory damage that drives multiple sclerosis relapses.

Trial Status

PONVORY was approved by the FDA in March 2021 based on the Phase 3 OPTIMUM study (NCT02425644), which showed it reduced annual relapse rates by nearly a third compared to teriflunomide (Aubagio). The drug is commercially available in the U.S. and Canada under Vanda's commercialization.

The Two-Sided Case

▲ Bull Case5
PONVORY is an FDA-approved, already-commercialized asset with a proven safety profile and over 10 years of clinical data, reducing regulatory risk.
Vanda acquired U.S. and Canadian rights for $100M in December 2023 and completed the FDA marketing authorization transfer, giving it full control over U.S. commercialization.
Q3 2026 PONVORY sales of $7.7M were up 10% year-over-year, and first-half 2026 sales of $14.1M were up 11% YoY, suggesting modest growth momentum.
Vanda's 2026 revenue guidance of $230-260M implies continued contribution from PONVORY alongside growth from Fanapt and new product launches.
Analyst consensus on VNDA is Strong Buy (9 Buy/Strong Buy vs 2 Hold, 0 Sell) with a mean price target of $11.50, implying ~198% upside from the current ~$3.86 price.
▼ Bear Case4
PONVORY operates in a crowded S1P modulator class facing generic fingolimod (Gilenya) pricing pressure, plus branded competition from Mayzent (siponimod, Novartis) and Zeposia (ozanimod, BMS).
PONVORY sales are modest and roughly flat: $27.4M in FY2025 (down 2% YoY) and $7.7M in Q3 2026 (down 2% sequentially from Q2 2026).
NCE-1 exclusivity expired in March 2025, opening the door for patent challenges; earliest generic entry could be as soon as November 2029 per DrugPatentWatch.
PONVORY is a small part of Vanda's overall story (~13% of 2025 revenue), so even strong commercial execution may not move the stock much.

Upcoming Catalysts

  • No PONVORY-specific binary catalysts are scheduled. Vanda's next major catalyst is the imsidolimab (Quimilza) PDUFA for generalized pustular psoriasis on December 12, 2026.
  • Q3 2026 earnings released today (October 28, 2026) provide the latest PONVORY sales data and 2026 guidance update.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vanda Pharmaceuticals Inc. 8-K VNDA ·Originating report

Sources · 10

Hover a chip for the title
1 prnewswire.com2 marketscreener.com3 prnewswire.com4 biospace.com5 en.wikipedia.org6 fda.gov7 drugs.com8 eureka.patsnap.com9 drugpatentwatch.com10 prnewswire.com